KR20230144019A - 항발작 치료제의 신속한 전달을 위한 방법 및 조성물 - Google Patents

항발작 치료제의 신속한 전달을 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20230144019A
KR20230144019A KR1020237026748A KR20237026748A KR20230144019A KR 20230144019 A KR20230144019 A KR 20230144019A KR 1020237026748 A KR1020237026748 A KR 1020237026748A KR 20237026748 A KR20237026748 A KR 20237026748A KR 20230144019 A KR20230144019 A KR 20230144019A
Authority
KR
South Korea
Prior art keywords
seizure
diazepam
composition
subject
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237026748A
Other languages
English (en)
Korean (ko)
Inventor
수니타 미스라
엔리케 제이. 카라자나
아드리안 엘. 라비노위치
스튜어트 매든
에드워드 티. 마지오
리차드 마이클 구스틴
Original Assignee
뉴렐리스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 뉴렐리스 인코포레이티드 filed Critical 뉴렐리스 인코포레이티드
Publication of KR20230144019A publication Critical patent/KR20230144019A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Lubricants (AREA)
  • Rolling Contact Bearings (AREA)
KR1020237026748A 2021-01-08 2022-01-07 항발작 치료제의 신속한 전달을 위한 방법 및 조성물 Pending KR20230144019A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163135291P 2021-01-08 2021-01-08
US63/135,291 2021-01-08
US202163276761P 2021-11-08 2021-11-08
US202163276760P 2021-11-08 2021-11-08
US63/276,761 2021-11-08
US63/276,760 2021-11-08
US202163284033P 2021-11-30 2021-11-30
US63/284,033 2021-11-30
PCT/US2022/011538 WO2022150540A1 (en) 2021-01-08 2022-01-07 Methods and compositions for rapid delivery of anti-seizure therapeutics

Publications (1)

Publication Number Publication Date
KR20230144019A true KR20230144019A (ko) 2023-10-13

Family

ID=82323232

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237026748A Pending KR20230144019A (ko) 2021-01-08 2022-01-07 항발작 치료제의 신속한 전달을 위한 방법 및 조성물

Country Status (6)

Country Link
US (2) US20220218598A1 (https=)
EP (1) EP4274618A4 (https=)
JP (1) JP2024502466A (https=)
KR (1) KR20230144019A (https=)
AU (1) AU2022206421A1 (https=)
WO (1) WO2022150540A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117580579A (zh) * 2021-06-10 2024-02-20 纽瑞莱斯有限公司 用于治疗儿科患者的癫痫发作病症的方法和组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
CA2756690C (en) * 2008-03-28 2016-08-16 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
EP2694076A4 (en) * 2011-04-01 2014-08-27 Cpex Pharmaceuticals Inc Nasal formulations of benzodiazepine
EP4085899A1 (en) * 2011-06-14 2022-11-09 Neurelis, Inc. Administration of benzodiazepine

Also Published As

Publication number Publication date
AU2022206421A1 (en) 2023-07-13
WO2022150540A1 (en) 2022-07-14
WO2022150540A9 (en) 2022-10-13
US20240299290A1 (en) 2024-09-12
US20220218598A1 (en) 2022-07-14
JP2024502466A (ja) 2024-01-19
EP4274618A4 (en) 2025-04-23
EP4274618A1 (en) 2023-11-15

Similar Documents

Publication Publication Date Title
Mitelpunkt et al. The safety, tolerability, and effectiveness of PTL-101, an oral cannabidiol formulation, in pediatric intractable epilepsy: A phase II, open-label, single-center study
Riddle et al. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial
EP3687576B1 (en) Use of cannabidiol in combination with norfenfluramine or fenfluramine in the treatment of epilepsy
de Vries et al. Tetrahydrocannabinol does not reduce pain in patients with chronic abdominal pain in a phase 2 placebo-controlled study
Tzadok et al. CBD-enriched medical cannabis for intractable pediatric epilepsy: the current Israeli experience
WALBURGA et al. Therapeutic effects and effects on actual driving performance of chronically administered buspirone and diazepam in anxious outpatients
Carr et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study
Mick et al. Impulsive-compulsive sexual behavior
US20060252761A1 (en) Augmentation of extinction via administration of sub-antimicrobial doses of D-cycloserine
BG107690A (bg) Метод за аналгезия
JP7321256B2 (ja) 片頭痛予防のためのラスミジタンの慢性的な夜間投薬
Carbone et al. Impulse control disorders in Parkinson’s disease: an overview of risk factors, pathogenesis and pharmacological management
CN114786660A (zh) 使用mtorc1调节剂的治疗方法
Lunardi et al. Olfactory stimulation induces delayed responses in epilepsy
Egeberg et al. Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances
Nardi et al. Respiratory panic disorder subtype: acute and long-term response to nortriptyline, a noradrenergic tricyclic antidepressant
Feng et al. Transcutaneous electrical acupoint stimulation as an adjunct therapy for obsessive-compulsive disorder: A randomized controlled study
US20240299290A1 (en) Methods and compositions for rapid delivery of anti-seizure therapeutics
McCall et al. Comparison of the efficacy of titrated, moderate-dose and fixed, high-dose right unilateral ECT in elderly patients
US12599611B2 (en) Methods and compositions for treating seizure disorders in pediatric patients
Zadikoff et al. Cannabinoid, CB1 agonists in cervical dystonia: failure in a phase IIa randomized controlled trial
Turner et al. Epilepsy in the oral and maxillofacial patient: current therapy
US20060084659A1 (en) Augmentation of psychotherapy with cannabinoid reuptake inhibitors
Waters et al. Impaired sexual function
Terao et al. Serotonin syndrome in a case of depression with various somatic symptoms: the difficulty in differential diagnosis

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230804

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250103

Comment text: Request for Examination of Application